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Abi-1 is an adaptor protein for Abelson kinase (c-Abl), and Abi-1 promotes the Abl-mediated phos-
phorylation of Mammalian Enabled (Mena) by binding both c-Abl and Mena. Here, we identiﬁed a
new phosphorylation site (Y398) in the SH3 domain of Abi-1, and disruption of Y398, combined with
the previously identiﬁed phosphorylation site Y213, signiﬁcantly weakens the binding of Abi-1 to c-
Abl. The SH3 domain of Abi-1 and the proline-rich domain of c-Abl are involved in this interaction.
Abi-1 phosphorylation at both sites stimulates the phosphorylation of Mena through the activation
of c-Abl kinase. The phosphorylation of Abi-1 also plays a role in enhancing the adhesion of Bcr-
Abl-transformed leukemic cells.
Structured summary of protein interactions:
Abi1 physically interacts with c-Abl by pull down (View Interaction 1, 2)
c-Abl physically interacts with Abi1 by anti bait coimmunoprecipitation (View Interaction 1, 2)
c-Abl physically interacts with Abi1 by pull down (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
c-abl is a proto-oncogene of Abelson murine leukemia virus en-
coded v-abl [1,2]. Structural and biochemical studies have revealed
that c-Abl can adopt a folded state that suppresses its catalytic
activity [3–5]. Translocation of c-abl on human chromosome 9 with
bcr on chromosome 22 generates t9:22 encoding the Bcr-Abl fusion
protein, which possesses aberrant kinase activity and causes
chronic myeloid leukemia (CML) in human. Cytoskeletal abnormal-
ities and altered cell adhesion are hallmarks of CML [6–8], and an
increased understanding of the regulatory and signaling pathways
associated with c-Abl dysregulation will provide insight into the
pathogenesis of CML and other hematologic malignancies induced
by Bcr-Abl expression.
Abl-interactor-1 (Abi-1), also known as E3B1 [9], was origi-
nally identiﬁed as an c-Abl-binding protein [10], and Abi-1 pro-chemical Societies. Published by E
olecule Cell Biology, Tohoku
u, Sendai, Miyagi 980-8578,
aruoka).motes the c-Abl-mediated phosphorylation of Mammalian
Enabled (Mena) [11] and BCAP [12]. Abi-1 is an adapter protein
that acts a bridge by binding both c-Abl and Mena, and Abi-1
may regulate the kinase activity and/or substrate recognition of
c-Abl. Abi-1 has also been suggested to play a critical role in
the leukemogenesis caused by Bcr-Abl [13–15], and it was re-
cently shown that phosphorylation of Abi-1 at Y213 down-regu-
lates the catalytic activity of non-myristoylated Abl by binding
its SH2 domain [16]. However, the interaction of a phosphopep-
tide with the SH2 domain of c-Abl induces a conformational
change in c-Abl, resulting in increased kinase activity [3,17].
Furthermore, phosphorylation of Y213 in Abi-1 is seen in several
Bcr-Abl-transformed leukemic cell lines [18]. Therefore, the
mechanism by which phosphorylation of Abi-1 contributes to
the regulation of c-Abl and oncogenic Bcr-Abl kinases remains
unclear. In this study, we identiﬁed Y398 in the SH3 domain of
Abi-1 as another major site of phosphorylation by c-Abl, and
showed that the SH3 domain of Abi-1 and the proline-rich do-
main of c-Abl are involved in this interaction. Finally, we exam-
ined the possible role of Abi-1 phosphorylation at Y213 and
Y398 in the modulation of c-Abl and Bcr-Abl kinases.lsevier B.V. All rights reserved.
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2.1. Plasmid and reagents
The plasmids pcDNA3-c-Abl, pEBG-Abi-1, FLAG-Abi-1, pEBG-
Mena have been described previously [11]. Bcr-Abl (p210) cDNA
was introduced into the pcxBSR retroviral vector to generate
pcxBSR-Bcr-Abl. The tyrosine to phenylalanine Abi-1 variants
Y213F with or without Y398F were made using the Quickchange
Site-Directed Mutagenesis kit (Stratagene) in pFLAG-CMV6 Abi-1.
DNA regions corresponding to the wild-type (WT) and P4X form
of the proline-rich domain of c-Abl (a.a. 518–880) were subcloned
into pEBG and expressed as a GST-tagged fusion protein in 293T
cells. WT and mutant Abi-1 were subcloned into the EcoRI site of
pGXGFP [19] to produce glutathione-S-transferase (GST)-tagged
fusion proteins. Western blot analysis was performed as previously
described [11]. The following antibodies were used: anti-Abl (8E9
and C-19; from Pharmingen and Santa Cruz Biotechnology, respec-
tively), anti-FLAG (M2; Sigma), anti-GST (C-14; Santa Cruz Biotech-
nology), anti-Abi-1 (1G9; a gift from Dr. Katsuko Tani, Tokyo
University of Pharmacy and Life Science [11]), anti-phosphotyro-
sine (4G10; Millipore), anti-actin (AC-74; Sigma), and anti-GFP
(MBL).
2.2. Cells
Plat-E cells (a gift from Dr. Toshio Kitamura, The University of
Tokyo, Tokyo, Japan [20]) and 293T cells were grown in Dul-
becco’s modiﬁed Eagle’s medium supplemented with 10% fetal
calf serum (FCS) and antibiotics. Ba/F3 cells were cultured in
RPMI-1640 medium supplemented with 10% FCS, 50 nM
b-mercaptoethanol and antibiotics plus 0.2% conditioned medium
from a mouse interleukin-3-overexpressing myeloma cell line
(a gift from Dr. Hajime Karasuyama, Tokyo Medical and Dental
University, Tokyo, Japan [21]). K562 cells were cultured in
RPMI-1640 medium supplemented with 10% FCS and antibiotics.
CHO-S-EcoR cells were described previously [19]. Stable cell lines
were obtained as described in the Supplementary materials and
methods.2.3. Phosphoproteome analysis of GST-Abi-1
Phosphorylated Abi-1 was puriﬁed from CHO cells stably
expressing GST-Abi-1 and c-Abl and subjected to Q-TOF LC-MS/
MS analysis. Details of analytical conditions and data are described
in the Supplementary materials and methods.
2.4. Kinase assay
The catalytic activity of c-Abl was measured as previously de-
scribed [22] with some modiﬁcations. HEK 293T cells co-express-
ing c-Abl and WT or mutant FLAG-Abi-1 were lysed, and c-Abl
was precipitated from cell lysates containing 1 mg of total pro-
tein using 1 lg of the anti-Abl antibody C-19 and Protein G-Se-
pharose beads. After four washes with kinase buffer (20 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM DTT) supplemented with
1 mM phenylmethylsulfonylﬂuoride, immunoprecipitated c-Abl
was mixed with the indicated concentrations of GST-Crk (a.a.
120–225) in a total volume of 20 ll kinase buffer supplemented
with 1 mM sodium orthovanadate and 10 mM MgCl2. The kinase
reaction was started by adding 0.5 lM ATP, incubated at 30 C
for 15 min, and stopped by the addition of SDS–PAGE sample
buffer with boiling for 5 min. Phosphorylation of GST-Crk was
detected by Western blotting using an anti-phosphotyrosine
antibody.2.5. Cell adhesion assay
Cells to be examined were seeded onto ﬁbronectin coated 96-
well plates (Biocoat; BD Bioscience) at a density of 5  104 cells
per well in 100 ll of appropriate culture media. Cells were spun
at 410 rpm for 2 min and incubated for 30 min at 37 C. Unat-
tached cells were removed by gentle washing with PBS three times,
and attached cells were ﬁxed with 4% paraformaldehyde in PBS.
The cells were stained with 1% Gentian violet for 10 min and
extracted in 1% SDS in water overnight. The absorbance of the
extracted Gentian violet was measured at 570 nm using a M-T
Max microplate reader (Molecular Devices).
3. Results and discussion
3.1. Identiﬁcation of sites of Abl phosphorylation in Abi-1
We ﬁrst wished to identify phosphorylation site(s) in Abi-1
responsible for the regulation of c-Abl, and we expressed WT and
kinase-deﬁcient (KD) Abl together with GST-Abi-1 in 293T cells.
GST-Abi-1 and associated proteins were precipitated with GST
beads and subjected to Western blotting with anti-phosphotyro-
sine and anti-Abl (8E9) antibodies. In cells expressing WT c-Abl,
Abi-1 was phosphorylated, while no Abi-1 phosphorylation was
detected in cells expressing only KD Abl (Fig. 1A). When cells were
incubated in the presence of imatinib, the phosphorylation of Abi-1
and the autophosphorylation of c-Abl were abrogated (data not
shown). Thus, in this system Abi-1 is phosphorylated solely by
c-Abl.
Two studies have identiﬁed Y213 as a site of phosphorylation in
Abi-1 [16,18], and we generated an Abi-1 point mutant (Y213F)
and examined its phosphorylation status in 293T cells (Fig. 1B).
The degree of phosphorylation of the Y213F mutant was less than
that seen for WT Abi-1, but phosphorylation of the Y213F mutant
still occurred, suggesting the presence of another phosphorylation
site(s) in Abi-1 (Fig. 1C). We used mass spectrometry (MS) to
examine phosphorylated GST-Abi-1 puriﬁed from CHO cells co-
expressing c-Abl to determine the sites of Abi-1 phosphorylation.
As expected, LC/Q-TOF analysis identiﬁed Y213 as a phosphoryla-
tion site, but an additional site was found at Y398 in the SH3 do-
main (Supplementary Fig. S1).
To validate the LC/Q-TOF analysis, we co-transfected 293T cells
with plasmids encoding c-Abl and WT GST-Abi-1 or the Abi-1 tyro-
sine to phenylalanine mutants Y213F, Y398F or Y213/398F (2YF).
Phosphorylation levels of Abi-1 were signiﬁcantly reduced in cells
expressing the single mutants compared to WT Abi-1, and Abi-1
phosphorylation was further reduced in cells expressing the 2YF
double-mutant (Fig. 1D). Additionally, the amount of c-Abl co-pre-
cipitated with GST-Abi-1 was also reduced in the cells expressing
the tyrosine mutants, reﬂecting the decreased phosphorylation
levels (Fig. 1E). These data demonstrate that Y398 and Y213 are
the major phosphorylation sites of Abi-1, and these ﬁndings were
conﬁrmed using reciprocal immunoprecipitation experiments
(Supplementary Fig. S2). However, introduction of phosphomimic
mutations of Y213 and Y398 did not enhance c-Abl binding (data
not shown), suggesting that a negative charge may not be the sole
determinant for this interaction. Moreover, the 2YF mutant re-
tained some residual phosphorylation, suggesting that minor phos-
phorylation site(s) other than Y213 and Y398 exist in Abi-1.
3.2. Identiﬁcation of domains responsible for the interaction of Abl and
Abi-1
Our results suggest that the phosphorylation status of Y213 and
Y398 affects the interaction of Abi-1 and c-Abl. The C-terminal
Fig. 1. Identiﬁcation of phosphorylation sites in Abi-1. (A) Phosphorylation of Abi-1 is dependent on c-Abl kinase. GST-Abi-1 was expressed together with WT or KD c-Abl in
293T cells. GST-pull down of GST-Abi-1 (left panel) and immunoprecipitation with c-Abl (right panel) are shown. (B) Phosphorylation of Abi-1 occurs on residues Y213 and
Y398. Phosphorylation sites identiﬁed as described in Supplementary Fig. S1 are shown (upper panel). Y to F substitution mutants of Abi-1 are shown (lower panel); X denotes
the positions of the mutated tyrosine residues. Pro-rich: proline-rich region, PP: poly-proline structure, SH3: SH3 domain. (C) Phosphorylation of Abi-1 by c-Abl occurs
primarily on residues Y213 and Y398. 293T cells were co-transfected with expression plasmids encoding c-Abl and either WT or mutant GST-Abi-1 as in (A). Whole cell
lysates were subjected to immunoblotting with anti-Abl (WCL). (D, E) Quantiﬁcation of (C). Densitometric analysis of the phosphorylation of GST-Abi-1 (D) and co-
precipitation of c-Abl with GST-Abi-1 (E) are shown. Data show the means ± S.D. of three independent experiments, and all were in the linear range of detection. Statistical
analysis was performed using the Student’s t-test. ⁄⁄⁄P < 0.001 and ⁄⁄P < 0.01.
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tion with the SH3 domain of Abi-1 [10], and the SH3 domain of
c-Abl contributes to this interaction by binding the PXXP motif of
Abi-1 (Pro-rich in Fig. 2A) [13]. We introduced mutations in
c-Abl and Abi-1 to more precisely identify the protein domains
required for this interaction.
We next wished to determine which domains of Abi-1 are re-
quired for its interaction with c-Abl, and we focused on the SH3 do-
main of Abi-1 as a putative interacting region based on a previousreport [10]. Indeed, deletion of the SH3 domain (DSH3) or intro-
duction of a point mutation (W421K) in the SH3 domain of Abi-1
abrogated its interaction with c-Abl (Fig. 2A and B). It was previ-
ously reported that deletion of the SH3 domain of Abi-1 did not af-
fect its binding to other proteins including syntaxin and Wave2
[23], suggesting that the SH3 domain is not required for Abi-1
function. However, phosphorylation of Abi-1 was also substantially
reduced in the SH3-domain variants (Fig. 2B), suggesting that an
intact SH3 domain supports the interaction of Abi-1 with c-Abl
Fig. 2. Interaction of c-Abl and Abi-1. (A) Cartoon of WT and mutant Abi-1 constructs is shown. (B) The interaction of c-Abl and Abi-1 depends on the SH3 domain of Abi-1.
WT or mutant GST-Abi-1 was co-expressed with c-Abl in 293T cells. GST-Abi-1 and associated proteins were precipitated from cell lysates with glutathione beads and
analyzed by SDS–PAGE and Western blotting with anti-Abi-1, anti-Abl N-terminus (8E9), anti-GST or anti-phosphotyrosine antibodies. (C) Cartoon of WT and mutant of Abl
constructs is shown. WT: wild-type, W118K: SH3 mutant, K290M: kinase activity-deﬁcient mutant (KD), P2X (P548A + P592A): double proline-motif mutant, P4X
(P548A + P592A + P634A + P781A): quadruple proline-motif mutant. Pro-rich: proline-rich domain, AB: actin binding domain. (D) The interaction of c-Abl and Abi-1 depends
on proline residues in c-Abl. WT or mutant c-Abl was co-expressed in 293T cells with GST-Abi-1. GST-Abi-1 and associated proteins were precipitated and analyzed by
Western blotting as in B). The densities of the immunoblot rows of anti-pY and -Abl were quantiﬁed, and the intensities were normalized to that c-Abl WT. Fold change is
shown below each blot. (E) Cartoon of WT and the P4X proline-rich domain mutant of c-Abl (a.a. 519–880). (F) P4 residues are essential for the interaction with Abi-1. WT or
the P4X mutant shown in (E) was co-expressed in 293T cells with FLAG-Abi-1 WT, YF or 2YF. GST-c-Abl and associated proteins were precipitated and analyzed by Western
blotting as in (B).
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among other SH3 domain-containing proteins, and it is found
immediately after the ﬁrst b-strand. This residue is presumed to
play a role in the binding to target peptides [24]. Therefore, we
speculate that the phosphorylation of Y398 plays a role in thehomo- and/or hetero-oligomerization of the Abi-1 through the
SH3 domain [25]. However, the mechanism by which Y398 con-
tributes to this process remains unclear. The residual phosphoryla-
tion seen in both the WK and DSH3 variants might reﬂect the
phosphorylation of residue(s) outside of this region, e.g. Y213, by
838 M. Sato et al. / FEBS Letters 585 (2011) 834–840c-Abl, a small amount of which was precipitated with the Abi-1
SH3-domain variants (Fig. 2B).
We next wished to determine the region of c-Abl responsible for
its interaction with Abi-1, and we generated mutants in the SH3,
kinase (KD), and proline-rich domains of c-Abl. Previous studies
have identiﬁed residues W118 and K290 in the SH3 and KD,
respectively, as being important for c-Abl function. We also fo-
cused on the proline-rich domain of c-Abl as a putative interaction
site for the Abi-1 SH3 domain. WT and mutant Abl constructs were
co-expressed with GST-Abi-1 in 293T cells, and GST-pull down as-
says were performed. The amount of c-Abl co-precipitated with
Abi-1 was reduced, consistent with the reduced phosphorylation
following the introduction of the P2X mutation, but mutation of
four proline residues (P4X) greatly reduced both the co-precipita-
tion of Abl and phosphorylation of Abi-1 (Fig. 2D). A previous study
reported that the kinase activity of c-Abl was not affected by this
mutation [26]. Thus, the proline-rich domain of c-Abl containingFig. 3. Phosphorylation of Abi-1 increases the catalytic activity of c-Abl and enhances th
was co-expressed with FLAG-Abi-1 in 293T cells. The kinase activity of immunoprecipitat
(a.a. 120–225) are indicated in lM, and Crk phosphorylation was detected by Western b
Abi-1 were also examined. (B) Abi-1 phosphorylation enhances the kinase activity of c-Ab
FLAG-Abi-1 in 293T cells. Immunoprecipitated c-Abl was incubated with 3.0 lM GST-C
upper panel. (C, D) GST-Mena and FLAG-Abi-1 were expressed in 293T cells together w
blotting as described in Section 2. (E) WT or mutant GST-Abi-1 was expressed in 293T cel
analyzed as in Fig. 1.residues P634 and P781 is primarily responsible for mediating its
interaction with Abi-1, and we conﬁrmed this by demonstrating
the direct interaction of the WT proline-rich domain of c-Abl, not
a P4X construct, and Abi-1 (Fig. 2E and F). The YF mutants could
interact with the c-Abl proline-rich domain, demonstrating that
the YF mutation per se does not affect the binding activity of
Abi-1 and the tertiary structure adopted by full-length c-Abl may
block the direct interaction of its proline-rich domain and Abi-1.
3.3. Phosphorylation of Abi-1 increases the catalytic activity of c-Abl
in vitro and enhances the phosphorylation of Mena by c-Abl
The interactionof c-AblwithAbi-1was affectedby thephosphor-
ylation status of Abi-1 (Figs. 1 and 2), suggesting that the activity of
c-Abl may be modulated by Abi-1 binding. We next examined the
effects of Abi-1 phosphorylation on the activity of c-Abl kinase. We
immunoprecipitated c-Abl from cells co-expressing WT or mutante phosphorylation of Mena by c-Abl. (A) Abi-1 activates c-Abl kinase activity. c-Abl
ed c-Abl was measured using GST-Crk as a substrate. The concentrations of GST-Crk
lotting using an anti-phosphotyrosine antibody. The expression levels of c-Abl and
l. c-Abl was expressed together with WT FLAG-Abi-1 or Y213F, Y398F or 2YF mutant
rk, and the relative phosphorylation level of GST-Crk is indicated at the bottom of
ith c-Abl (C) or Bcr-Abl (D). GST-Mena was precipitated and analyzed by Western
ls together with Bcr-Abl. Phosphorylation of Abi-1 and co-precipitated Bcr-Abl were
Fig. 4. Adhesion of leukemic cells is enhanced by expression of WT Abi-1. (A
Western blotting of Ba/F3 and K562 cells expressing WT or mutant GFP-Abi-1 is
shown. Anti-actin was used as the loading control. (B) Abi-1 expression enhances
leukemic or Bcr-Abl expressing cell adhesion. Cell adhesion was assessed as
described in Section 2. Data shown are the means ± S.D. of quadruplicates
Statistical analysis was performed using a Student’s t-test. ⁄⁄⁄P < 0.001.
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substrate for c-Abl. The speciﬁc activity of Abl kinase was enhanced
by co-expressing WT Abi-1 (Fig. 3A), but expression of the Y213F,
Y398F, or 2YF mutant Abi-1 constructs reduced the kinase activity
of c-Abl by approximately 50% (Fig. 3B), suggesting that the concur-
rent phosphorylation of Y213 and Y398 contributes to the modula-
tion of c-Abl kinase activity. However, Xiong et al. [16] reported
that a Y213 phosphopeptide, but not an unphosphorylated form,
inhibited the kinase activity of non-myristoylated human c-Abl.
We presume that an allosteric effect induced by the binding of the
phosphopeptide to c-Abl could prevent the binding of full-length
Abi-1.
It is hypothesized that Abi-1 upregulates the catalytic activity of
Abl by binding both c-Abl and its substrates including Mena and
BCAP [11,12]. To examine this in greater detail, we assessed
whether the phosphorylation state of Y398 and/or Y213 of Abi-1
affects c-Abl-mediated phosphorylation. Abl-mediated phosphory-
lation of Mena was greatest when WT Abi-1 was present, and co-
expression of the Abi-1 YF mutants substantially suppressed Mena
phosphorylation (Fig. 3C). Thus, phosphorylation of Abi-1 by c-Abl
enhances the c-Abl-mediated phosphorylation of Mena. It was also
previously reported that expression of Abi-1 did not enhance the
c-Abl-mediatedphosphorylation of c-Cbl [11]. Taken together, these
observations suggest that phosphorylation of Abi-1 at Y213 and
Y398 is involved in the phosphorylation of Mena through c-Abl.
3.4. Abi-1 tyrosine-mutants fail to enhance the adhesion of leukemic
cells to ﬁbronectin
Accumulating evidence suggests that Abi-1 plays an important
role in Bcr-Abl-induced leukemia, and a prominent role in affecting
cell adhesion has been proposed [13,15]. Our data indicate that the
phosphorylation status of Abi-1 affects the kinase activity of c-Abl
and the phosphorylation of Mena (Fig. 3C). In contrast to what was
seen for c-Abl, phosphorylation of Mena by Bcr-Abl occurred in the
absence of Abi-1 expression (Fig. 3D). Some enhancement of Mena
phosphorylation by Bcr-Abl was seen in the presence of Abi-1, but
the Abi-1 YF variants had only a minimal effect on Mena phosphor-
ylation (Fig. 3D). In fact, Bcr-Abl could interact with/phosphorylate
Abi-1, and the YF mutations had minimal effects on both the phos-
phorylation and binding of Abi-1 (Fig. 3E). These data suggest that
the phosphorylation of Abi-1 still contributes to the Bcr-Abl-med-
iated phosphorylation of Mena, but weakly. This likely reﬂects dif-
ferences in the structure and function of c-Abl and Bcr-Abl.
Therefore, we next examined the mechanism by which Abi-1 phos-
phorylation affects the adhesion of leukemic cells.
We used the human erythroblast cell line K562, which was de-
rived fromapatientwith Bcr-Abl-positive leukemia, and Ba/F3 cells,
a murine pro-B cell line, and its Bcr-Abl-transformed derivative to
study the role of Bcr-Abl. When GFP-Abi-1 and its variants were
introduced into these cell lines (Fig. 4A) and cell adhesion was as-
sessed, little adhesion of the parental Ba/F3 cells to ﬁbronectin
was observed, but expression of Bcr-Abl increased the number of
adherent cells (Fig. 4B, upper panel). Overexpression of WT GFP-
Abi-1 in Bcr-Abl-transformedBa/F3 cells further increased the num-
ber of adherent cells. Reciprocal effects on cell adhesion were seen
when Abi-1 expression was knocked-down [15]. However, expres-
sion of the Abi-1 mutants Y213F, Y398F or 2YF did not affect the
adhesion of both Ba/F3 and Bcr-Abl-positive K562 cells (Fig. 4B),
demonstrating that the phosphorylation of Abi-1 at both Y213 and
Y398 promotes the adhesion of leukemic cells. Since the c-Abl-med-
iated phosphorylation of Lamellipodin (Lpd) increases its interac-
tion with Ena/VASP proteins and regulates cytoskeletal dynamics
at the cell leading edge [27], the Bcr-Abl-mediated phosphorylation
of Abi-1 (Fig. 3D andE)may regulate the localization and/or function
of the Ena/VASP proteins including Mena in this process.)
.In conclusion, we identiﬁed a new phosphorylation site in Abi-1,
Y398, anddemonstrated that thephosphorylation state of both Y213
and Y398 could modulate Abl-Abi-1 interaction. In this context, the
phosphorylation of Y213 and/or Y398 may contribute to the trans-
activation of c-Abl-mediated Mena phosphorylation. We also pro-
vide data that phosphorylation of Abi-1 at both sites may contribute
to the altered cell adhesion seen in Bcr-Abl expressing cells.
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